The U.S. Food and Drug Administrationon approved Johnson & Johnson's nasal spray antidepressant that is chemically similar to often-abused ketamine, marking the first advance in treating depression in more than 30 years.
The treatment comes with a boxed warning, flagging the risk for sedation and difficulty with attention, judgment and thinking, abuse and misuse, and suicidal thoughts after administration of the drug.
Spravato is a chemical mirror image of anesthetic ketamine, which is abused as a recreational party drug.
Spravato has been touted as an asset with blockbuster potential and is expected to improve investor sentiment toward the growth prospects of J&J's pharma unit Janssen, as its top-selling rheumatoid arthritis drug Remicade faces increased competitiobn from cheaper biosimilars.
No comments:
Post a Comment